Medical professionals from the USA, Jordan, and Qatar reported an unusual clinical case: an elderly woman was initially suspected of having a myocardial infarction. However, it turned out that her condition was caused by stress cardiomyopathy, which arose from an extremely intense feeling of happiness during her daughter's wedding. After a course of treatment, the woman's heart function recovered to its previous levels.
Takotsubo cardiomyopathy, also known as stress cardiomyopathy or 'broken heart syndrome,' belongs to the group of non-ischemic cardiomyopathies. It is characterized by the apex of the left ventricle expanding and reducing its contractile ability, while the base of the ventricle maintains normal function. This syndrome is usually triggered by severe stress, such as the loss of a loved one, as well as conditions like shock, sepsis, hemorrhagic stroke, or pheochromocytoma.
The first documentation of this disease occurred in 1983 thanks to Japanese researchers, who later observed and published other similar cases, naming the syndrome after the octopus-like shape of the heart (takotsubo). The form associated with excessively positive emotions is much rarer and was described for the first time only in 2016.
Raed Ababneh from the University Medical Center of Ocean County in New Jersey and his team described the case of a 65-year-old woman. She sought medical attention complaining of shortness of breath and angina that lasted for three days. Immediately before this, she attended her daughter's wedding, where she experienced very strong positive emotions. Her medical history noted arterial hypertension, type 2 diabetes, and dyslipidemia.
For several months before seeking care, the woman had suffered from chest pains that did not match typical symptoms of angina and was under outpatient observation. Blood tests and ECG showed ST segment elevation in anterolateral leads, which is a sign of acute myocardial infarction. The patient was urgently transported to a tertiary care hospital. A repeat ECG showed that the ST elevation had disappeared, and the symptoms subsided. The woman was hospitalized in the intensive care unit with the diagnosis of acute coronary syndrome.
Emergency coronary angiography revealed no narrowing of the coronary vessels, but an bulging of the heart apex was identified. Echocardiography showed apical akinesis with hyperkinesis of the rest of the left ventricle and a significant decrease in ejection fraction to 35% (compared to 58% five months prior). Blood tests revealed elevated levels of cardiac damage markers troponin (up to 717 nanograms per liter) and heart failure marker N-terminal pro-B-type natriuretic peptide (up to 633 picograms per milliliter), which subsequently began to decrease.
Cardiac MRI ruled out edema, infarction, or fibrosis. Based on all the data, the patient was diagnosed with Takotsubo cardiomyopathy. She was prescribed a treatment regimen and referred for outpatient follow-up at a heart failure clinic. Soon her condition improved, and she was able to return to her normal life without restrictions. Subsequent echocardiography demonstrated a significant recovery of left ventricular function, reaching an ejection fraction of 56%.
It is worth noting that according to a systematic review and analytical modeling, the global prevalence of peripheral artery disease among individuals over 25 years old in 2023 was 6.58%, corresponding to 316.54 million cases. Women were more frequently affected by these pathologies, and the main risk factors were smoking, diabetes, hypertension, and hypercholesterolemia. These results were published in The Lancet Global Health.
As the popularity of injectable weight-loss drugs grows, healthcare professionals remind residents of South Africa that the origin of the medication can be as significant as its composition. A more affordable version of the semaglutide molecule, used in the drug Ozempic, will soon be available in South Africa, and this is related to goals that go beyond just the weight loss trend.
Starting July 27, Novo Nordisk South Africa, in collaboration with Acino, which is part of Arcera, will release an authorized and more budget-friendly version of the well-known semaglutide molecule. The companies stated that this initiative aims to expand access to treatment for people suffering from type 2 diabetes.
Despite the widespread coverage of Ozempic on social media, there is a serious and quiet crisis in the healthcare sector behind this hype. Over 2.3 million adults in South Africa, accounting for about 7.2% of the population, live with type 2 diabetes, and access to this medication is a daily necessity for them, not a matter of appearance.
The scientific basis of this drug has a fascinating history. Decades ago, scientists studying blood sugar regulation discovered a unique peptide in the venom of the Gila monster, a slow-moving desert lizard. This natural compound perfectly mimicked human gut hormones, slowing digestion and signaling satiety to the brain. Today, this advanced science is embodied in semaglutide.
The product is registered by the South African Health Products Regulatory Authority (SAHPRA). According to a press release, it is manufactured using the same active pharmaceutical ingredient, manufacturing process, and delivery device as the original semaglutide drug. It is important to emphasize that this is not some mysterious 'Ozempic alternative' bought through social media or an unverified online seller, but an authorized copy created by the original manufacturer to provide the same expected benefits at a lower price.
Demand for semaglutide, GLP-1 class drugs, and weight-loss injections is rapidly increasing, while issues of availability, cost, and supply remain highly relevant. Although the drug naturally aids in weight control, SAHPRA emphasizes that its primary registered use in South Africa is for diabetes management and cardiovascular health protection.
Sarah Northcross, General Manager of Novo Nordisk South Africa, stated: 'We are proud to introduce an affordable, authorized copy of semaglutide to help expand access for patients across South Africa.' She added that 'this launch reflects our ongoing commitment to advancing changes in the prevention and treatment of serious chronic diseases.'
An authorized copy differs from a random generic, unregulated compounded drug, or a product purchased from an online seller claiming to contain semaglutide. Novo Nordisk asserts that this authorized copy uses the same SAHPRA-registered active pharmaceutical ingredient, manufacturing process, production lines, and delivery device as the original semaglutide product.
This is significant because SAHPRA has repeatedly warned South Africans about counterfeit, substandard, and unauthorized GLP-1 products sold through websites, social media, and unofficial channels. The regulator warns that goods acquired outside the legal supply chain may contain incorrect amounts of active substance, harmful impurities, a complete absence of the active component, or non-sterile material unsuitable for injection.
Cases of law enforcement have also been recorded in South Africa regarding the illegal manufacture and distribution of unregistered GLP-1 and GIP medications, including products advertised for weight loss. Thus, while the phrase 'cheaper semaglutide' naturally attracts attention, the safety message is equally important: a lower price does not mean purchasing from an unverified source.
John Norman, Regional Managing Director of Acino Africa, noted: 'Acino is fully committed to Novo Nordisk's dedication to improving patient well-being by increasing access to this vital treatment.' He continued: 'This collaboration supports Acino's long-term goal of expanding access to high-quality medicines where they are needed most by patients.'
For ordinary South Africans, the question is no longer whether semaglutide will remain part of medical discussions, as this is obvious. The more important question is whether the next chapter of the GLP-1 revolution can move beyond social media, celebrity weight loss stories, and expensive private prescriptions, becoming safer and more accessible for people who genuinely need medical treatment. Patients should not start, stop, or change semaglutide treatment without consulting a qualified healthcare professional. SAHPRA advises obtaining semaglutide medications only through licensed healthcare providers and pharmacies.
} , 2. {A shocking incident related to school meals has occurred in the Supaul district of Bihar. It was reported that more than one hundred students suddenly felt unwell after having lunch on Wednesday at Mirjawa Middle School, located in the Triveniganj sector.
Students claimed that a dead scorpion was found in the vegetable curry served. Panic ensued within the school complex. The school administration and local residents promptly transported a large number of children to the Triveniganj district hospital using various vehicles, causing temporary chaos at the hospital.
Fortunately, after receiving first aid at the hospital, the condition of all children stabilized. According to doctors, all students are not in danger and are under constant monitoring.
According to available information, rice and a vegetable dish made of potato and lentils were served to the children on Wednesday. Students stated that they discovered a dead scorpion in the vegetables during the meal, although most children had already eaten by then. Soon after eating, many children began complaining of a burning sensation in their throat, stomach pain, vomiting, dizziness, and anxiety. The situation quickly escalated: some children's conditions worsened, others started vomiting, and some became unconscious.
Upon noticing the deterioration of health, the school administration and teachers immediately sent all affected children for treatment. The arrival of this information attracted the attention of administrative officials, who also arrived at the scene.
The Director of the School Meal Program (DPM), Pankaj Kumar Singh, stated that after receiving notification from the District Education Officer (DEO), all information regarding the case was reviewed. Initial reports indicate that many children developed stomach aches and vomiting after consuming the school meal. He confirmed that some students alleged the presence of a scorpion in the food. A full investigation is currently underway, and if any negligence is found, the responsible parties will be severely punished.
The administration also stated that food samples would be tested to determine the exact cause of the children's health deterioration.
Dr. B.N. Paswan from the Triveniganj district hospital noted that over one hundred children were brought to the hospital after consuming the school meal. All children exhibited symptoms such as stomach pain, headaches, vomiting, and anxiety. After receiving emergency care, the condition of all students normalized, and none are in critical condition. Officials emphasized that they take the entire situation seriously, and it will only become clear after the investigation report whether there was indeed a scorpion in the food and who is responsible for the incident.
